STEM-27. THE ALTERATION OF IMMUNOSUPPRESSIVE FUNCTION IN GLIOBLASTOMA WITH UNDIFFERENTIATED TRANSFORMATION

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2018-11, Vol.20 (suppl_6), p.vi249-vi249
• Main Authors: Yamamuro, Shun, Hanashima, Yuya, Yoshimura, Sodai, Sano, Emiko, Ueda, Takuya, Yoshino, Atsuo
• Format: Article
• Language: English
• Subjects: Abstracts
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/noy148.1034

Abstract Glioma stem-like cells (GSCs) are strongly related to the treatment resistance in glioblastoma (GBM). GSCs differentiate into differentiated glioma cells (non-GSCs), and lose the stem cell features such as self-renewal, pluripotency and tumorigenesis. However, several study have demonstrated that GSCs and non-GSCs could convert between each other. Recently, immunotherapy has been attracting attention as a new GBM therapy. Indoleamine 2,3-dioxygenase (IDO), the enzyme for Tryptophan metabolism, is involved in the ability of GBM to escape from immune surveillance, and show immunosuppressive function. In this study, we investigated the difference of IDO expression between GSCs and non-GSCs to search a new therapeutic target for GBM. We used the human malignant glioma cell lines U-251MG and Rev-U-251MG, which was established by culturing U-251MG cells in serum-free media. Rev-U-251MG formed spheres with increased level of Nestin and Nanog expression. We regarded Rev-U-251MG as a GSCs cell line model and investigated the expression of IDO. The expression levels of IDO mRNA and protein were increased in Rev-U-251MG compared to the expression in U-251MG. The expression levels of IDO1 mRNA were analyzed by the quantitative reverse transcription PCR (p